Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

History

Adicet Bio was founded in 2016 with the aim of using monoclonal gamma delta T cells to treat cancer. In just a few years, with the help of our investors, Adicet has been able to develop groundbreaking technologies, secure breakthrough funding and secure strategic partnerships.

Mission

To enable a future where gamma delta T cells are available to everyone in need of cancer therapy and improve the lives of cancer patients.

Vision

To be the leading gamma delta T cell therapeutics company in the world.

Key Team

Dr. Francesco Galimi M.D., Ph.D. (Chief Medical Officer & Sr. VP)

Ms. Amy Locke (Head of HR)

Dr. Nancy L. Boman M.D., Ph.D. (Sr. VP & Chief Regulatory Officer)

Dr. Donald Healey (Chief Technology Officer)

Dr. Blake Aftab Ph.D. (Sr. VP & Chief Scientific Officer)

Recognition and Awards

Adicet Bio has been a winner of multiple prestigious awards, including the MIT Technology Review's Innovators Under 35 award and Fast Company's Most Innovative Companies in Healthcare award.